$0.495
-0.309 (-62.50%)At close
LYRA News
LYRA Events
Lyra Therapeutics Voluntarily Files for Delisting
Lyra Therapeutics announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission on Monday, April 20, 2026, to remove its common stock from listing and registration on The Nasdaq Stock Market. As previously disclosed, trading in the Company's common stock was suspended by Nasdaq on March 17, 2026. Although Nasdaq has indicated it intends to file its own Form 25 after all internal procedural periods have run, it has not yet done so. The Company is therefore voluntarily filing Form 25 in order to proceed with deregistration.
Lyra Therapeutics Faces Delisting from Nasdaq
On February 2, Lyra Therapeutics received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that Nasdaq has determined to delist the company's common stock from The Nasdaq Stock Market. The company has requested a hearing before a Nasdaq Hearings Panel to appeal Nasdaq's determination.
Lyra Therapeutics Suspends LYR-210 Development and Reduces Workforce
Lyra Therapeutics, announced that its Board of Directors has decided to suspend further development of LYR-210, the Company's lead product candidate for the treatment of chronic rhinosinusitis. The Company also announced a workforce reduction impacting its remaining 28 employees and other cost-saving actions to preserve capital. Maria Palasis, Ph.D., Chief Executive Officer, President and Chair of the Board, and Jason Cavalier, Chief Financial Officer and Treasurer, are each being retained as consultants to support the Company's pursuit of strategic alternatives. The Company has engaged SSG Capital Advisors to assist with this effort. "In connection with the Company's review of strategic options, which was announced in May 2024, the Board has concluded that it is in the best interests of shareholders to cease Lyra's product development operations," said Dr. Palasis. "We are grateful for the contributions of our employees most of whom will leave Lyra as a result of this decision to discontinue development of LYR-210. Our priority moving forward is to evaluate and explore strategic alternatives to advance LYR-210 for the potential benefit of patients."
Lyra Therapeutics announces Q3 EPS of $3.38, below consensus estimate of $4.07
Reports Q3 revenue $25,000, consensus $154,250. "We are now focused on putting all the components in place for a new, confirmatory Phase 3 clinical trial to make progress toward a New Drug Application ("NDA") for LYR-210 as a six-month treatment for CRS patients without nasal polyps," said Maria Palasis, President and CEO, Lyra Therapeutics. "We are excited to move forward with our business strategy and to advance LYR-210 as a novel therapeutic option for millions of CRS patients who fail current medical therapy."
Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)
Reports Q2 revenue $183,000, consensus $181,250. "The positive results from our ENLIGHTEN 2 trial have enabled us to secure financing and are providing momentum to optimize our regulatory strategy and resume manufacturing activities, as we pursue our path to advance LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management," said Maria Palasis, president and CEO, Lyra Therapeutics, Inc. "We continue to review and analyze the totality of the dataset from the ENLIGHTEN 1 and ENLIGHTEN 2 trials as we execute on our business strategy and envision the opportunities ahead for LYR-210 to benefit patients with CRS."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.